Dublin, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biosimilars - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 71 companies including many key and niche players such as
- Amgen Inc. (US)
- Allergan Plc. (Ireland)
- Biocon Ltd. (India)
- Biopartners GmbH (Switzerland)
- Boehringer Ingelheim GmbH (Germany)
- Celltrion Inc. (South Korea)
- Cipla Ltd. (India)
- Cipla BioTec Private Ltd. (India)
- Dr. Reddy's Laboratories Ltd. (India)
- Eli Lilly and Company (US)
- EPIRUS Biopharmaceuticals, Inc. (US)
- Hospira, Inc. (US)
- Intas Biopharmaceuticals Ltd. (India)
- Merck KGaA (Germany)
- Mylan N.V. (US)
- Pfizer Inc. (US)
- Samsung Bioepis Co., Ltd. (Korea)
- Sandoz International GmbH (Germany)
- STADA Arzneimittel AG (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
Key Topics Covered: 1. MARKET OVERVIEW Introduction to Biosimilars Biosimilars Set to Revolutionize Healthcare Sector Biosimilars Offer Great Promise despite Challenges Specific Guidelines for Biosimilars in Various Countries with Year of Publication List of Approved Biosimilars & Pending Biosimilar Applications in the EU List of Approved Biosimilars & Pending Biosimilar Applications in the US List of Approved Biosimilars in South Korea Biosimilars Find More Growth in Emerging Markets Comparison of Entry Barriers for Biogenerics in Select Global Markets Market Drivers Patent Expiry of Leading Biopharmaceuticals Leads Way for Biosimilars Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Cost Containment Measures Growing Aging Population Presence of Major Players Growth Restraints Uncertain Regulations High Lead-time High Manufacturing Costs Delivery and Commercialization Automatic Substitution Other Impediments to Market Acceptance Strategies to Aid Survival of Companies 2. RECENT BIOSIMILAR APPROVALS AND PIPELINE ANALYSIS Biosimilar Approvals in 2016, 2015, & 2014 Select Biosimilar Candidates in Late-Stage Pipeline: 2016 Biosimilars in Pipeline for Major Biologic Drugs: 2016 Increasing Collaborations, Licensing Routes and Partnerships Indian & Chinese Companies to Emerge Strong in Western Markets Improved Regulatory Framework European Union Ahead in the Biosimilars Race Biosimilars Regulatory Agencies in Select Regional Markets US Passes Act to Create Biosimilars Pathway, Finally 3. MARKET DYNAMICS & TRENDS Increased Penetration of Biosimilars Implications for Manufacturers Efforts to Push Up Biosimilar Adoption Improvements in Nomenclature and Interchangeability Contract Manufacturing Favored by Emerging & Major Biosimilar Players Companies Eye Human Insulin Biosimilars Monoclonal Antibodies A Key Growth Segment for Biosimilars Approved Monoclonal Antibodies for Therapeutic Use: 1986-2014 Biobetters: Potential Industry Challenge? High Cost of Biologics Favorable for Biosimilars Growing Biosimilars Market A Clear Advantage for Bioseparation Technologies 4. GLOBAL BIOLOGICS MARKET Global Biopharmaceutical Drug Market A Primer US The Largest Biologics Market Worldwide Increasing Share of Biotechnological Drugs to Drive Biosimilars Market Intensifying Consolidation Activity Recent M&A Activity in the Biologics Industry: 2014 & 2015 5. PRODUCT OVERVIEW Introduction Characteristics of Biosimilars Biological Drugs Biological Drugs Manufacturing Process Development Cycle of Biosimilars Industry Participants 6. PRODUCT APPROVALS/INTRODUCTIONS Mylan and Biocon Co-develop trastuzumab Biosimilar EC Approves Remicade Biosimilar Flixabi® Developed by Samsung Bioepis Samsung's BLA for Remicade Biosimilar Accepted by USFDA EMA Approves rituximab Biosimilar Developed by Sandoz EC Approves New Route of Administration for Sandoz's Biosimilar Binocrit USFDA Approves INFLECTRA, Celltrion's Biosimilar to Remicade Japanese Ministry Approves Biocon's Biosimilar Insulin Glargine EMA Accepts Sandoz's MAA for Neulasta Biosimilar FDA Accepts Amgen's BLA for ABP-501 7. RECENT INDUSTRY ACTIVITY Alvotech Acquires Baliopharm GmbH Dr. Reddy's Inks Collaboration Agreement with TR-Pharm Premier and Oncobiologics Collaborate to Enhance Biosimilars Adoption Sandoz Acquires Rights to infliximab Biosimilar from Pfizer Sandoz Enters into Exclusive License Agreement with Kyowa Hakko Kirin Mylan Enters Into Biosimilars Development Partnership with Momenta Pharmaceuticals Merck to Bring Biosimilars to Canada through its Agreement with Samsung EPIRUS Biopharmaceuticals to Expand Biosimilar Pipeline through Acquisition of Bioceros Pfizer Acquires Hospira Astrazeneca Enters into JV with Fujifilm Kyowa Kirin Biologics 8. FOCUS ON SELECT MARKET PLAYERS 9. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 71 (including Divisions/Subsidiaries 77)
- The United States (15)
- Canada (1)
- Japan (3)
- Europe (25)
- - France (1)
- - Germany (8)
- - The United Kingdom (5)
- - Spain (1)
- - Rest of Europe (10)
- Asia-Pacific (Excluding Japan) (30)
- Latin America (1)
- Middle-East (2)
For more information about this report visit http://www.researchandmarkets.com/research/v3...iosimilars Related Topics: Biosimilars and Biosuperiors
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716